The PRWIRE Press Releases https:// 2018-12-12T20:50:52Z News: XENON First to Distribute NVIDIA’s Most Powerful AI System: NVIDIA DGX-2 2018-12-12T20:50:52Z news-xenon-first-to-distribute-nvidias-most-powerful-ai-system-nvidia-dgx-2 Melbourne December 13, 2018 - XENON Systems, a leader in high performance computing, data analytics and artificial intelligence solutions, is the first to secure rights to sell the NVIDIA DGX-2 and DGX-2H platforms across Australia and New Zealand. By exploiting greater model and data parallelism, NVIDIA DGX-2 can solve the world’s biggest AI challenges that demand the largest datasets and the most complex deep neural networks. This includes financial institutions, insurance, science research, and security scenarios where there’s a requirement for large-scale statistical analysis. XENON is the only ANZ NVIDIA Elite Solution Provider and partner authorised to sell NVIDIA DGX-2 in the ANZ region. The relationship builds on XENON’s experience selling NVIDIA DGX-1 platforms over the last 2 years, in which XENON has successfully deployed 20+ units into various industries, including telco, tertiary institutions, and government. “We are committed to assessing and learning about the newest technologies that come to market, and we remain uniquely placed to translating their adoption into viable business outcomes for Australian organisations. We are proud of our long standing relationship and work with NVIDIA, and are pleased to now offer the most advanced AI platform the DGX-2 series,” said Dragan Dimitrovici, CEO of XENON Systems. NVIDIA DGX-2 is the world’s largest GPU. It is the first 2-PFLOPS system with 16 fully interconnected GPUs and the revolutionary NVIDIA NVSwitch technology. DGX-2 enables unprecedented compute density and scale in the data centre. Delivering world-record AI performance, each DGX-2 system arrives fully integrated with NVIDIA’s Deep Learning software stack, which includes: ● Major AI frameworks: Caffe, Caffe2, TensorFlow, Microsoft Cognitive Toolkit, MXNet, Chainer, Theano, Torch, and more ● Fully containerised deployment with easy-to-use interface ● Available containers for HPC applications: Gamess, GROMACS, LAMMPS, MILC, NAMD, VMD, and more For more information, please visit https://www.xenon.com.au and for specific product information go :https://www.xenon.com.au/product/nvidia-dgx2/ and https://www.xenon.com.au/product/nvidia-dgx-2h/ About XENON With over two decades of experience in designing and deploying supercomputers, workstations, and servers, XENON is leading its customers to the forefront of high performance computing, data analytics, and artificial intelligence. Whether the application is life sciences, enterprise or public services, XENON contributes to all stages of planning, design, and deployment to enable its customers to gain value from their data immediately. By offering the latest CPU, GPU, storage, and data networking technologies from a wide variety of global partners XENON is able to work with customers prior to the decision phase to design best-of-breed solutions to match requirements. In addition to hardware, XENON also offers the world’s most innovative software in areas of predictive data analytics, artificial intelligence, real-time IoT streamed data analysis, high availability storage, and SDN. XENON consulting and professional services brings everything seamlessly together to ensure that solutions are designed to; best meet customer needs, are configured and fully tested for system robustness, and delivered on time. OXAIR’S OXYGEN SYSTEMS WIPE OUT HOSPITAL CYLINDER COSTS 2018-11-29T14:19:30Z oxair-s-oxygen-systems-wipe-out-hospital-cylinder-costs Oxair Gas Systems’ new India venture will be taking centre stage with the company’s showpiece oxygen generating equipment at next year’s Arab Health Show in Dubai’s World Trade Centre from January 28-31. Representatives from Oxair Gas Systems India P Ltd will be available on Stand H58 to give a demonstration and answer any questions about the company’s latest high purity oxygen delivery systems supporting the health service in even remote parts of the subcontinent, as well as providing a safer and cost-effective alternative to conventional cylinders in local hospitals and medical facilities. A leading global manufacturer of advanced gas process systems, Oxair’s Indian subsidiary will also be showcasing the OA120 Medical Oxygen Generator Pressure Swing Adsorption (PSA) system, which can produce the equivalent of 12 cylinders a day (7 M3 capacity). The company eagerly awaits the world’s healthcare decision-makers at Stand H58 in Centre Hall 2 to show them the amazing cost-saving and safety benefits of its systems compared to traditional gas cylinders. These high quality medical devices are designed to last and deliver consistent, high purity oxygen to hospitals and healthcare facilities of all sizes.   Oxair’s Medical Oxygen Generators PSAs are registered medical devices under ISO 13485, which makes them fully compliant for use in all hospitals and medical facilities around the globe regardless of remoteness. As the equipment provides hospitals with the ability to control their own supply of 94% pure oxygen, it eliminates the chance of succumbing to failures in the oxygen cylinder supply chain. Clinicians are guaranteed a constant source of high quality oxygen that can be piped directly to the patient’s bedside on demand. The system is designed with ease of use in mind and comes with a user-friendly full colour touch screen requiring no extensive technical training. In addition, due to high quality parts being used to produce superior valving and piping, the system requires less maintenance, has low power consumption and guarantees high performance levels throughout its long lifespan. The Arab Health Exhibition presents the perfect platform in a region where healthcare expenditure is accelerating to meet an anticipated rise in the number of patients. Over 700 projects involving hospitals, clinics and research centres worth billions of US dollars are under various stages of development. These developments will need regular supplies of life-saving gas. Installing oxygen generators can not only significantly reduce a hospital’s oxygen costs, but also improve the health and safety standards for its staff due to them no longer handling dangerous high-pressure cylinders while eliminating the noise pollution associated with their delivery. CEO at Oxair, Jim Newell explained: “This is a major show for Oxair India and a chance to connect with the right people us so early in the year in a vital target market. Oxygen generators are the future for healthcare to reduce the reliance on cylinders except as a back-up for medical needs.” Oxair’s technology is suitable for small to medium-sized hospitals and has minimal impact on the workplace thanks to its specially designed muffler which makes it one of the quietest PSA systems on the market. The system can be engineered to integrate with any existing system, or designed from scratch. Oxair’s medical oxygen generators can also be used to fill cylinders for backup use. Visit Oxair in Centre Hall 2, Stand H58 at the Arab Health Exhibition in Dubai where Oxair’s representatives will be delighted to answer any questions. Alternatively, if you are not able to attend the show but would like to know more visit www.oxair.com.au Australia officially ‘Ahead of the Global Curve’ in Animal Health 2018-11-20T07:23:28Z australia-officially-ahead-of-the-global-curve-in-animal-health OVER 100 of the nations leading parasitologists, veterinary authorities, industry and business leaders gathered in Western Sydney today to mark the official launch of an Australian led - global breakthrough in animal health.  A who’s who of faces from agriculture and the scientific community along with invited guests converged on Camden’s Belgenny Farm Thursday, in a ceremony to announce what’s been labelled the most significant shakeup in veterinary parasitology in 40 years.  Hosted by CEO of the International Animal Health Products group, Mr Chris Lawlor, the event was the culmination of almost 20 years research and development along with millions of dollars in investment.  Addressing the lunchtime audience, Mr Lawlor said the release of ‘BioWorma’ initially came about as a result of work being done by the CSIRO, where the opportunity presented itself to play an active role in the advancement of animal health, both domestically and around the world. Through the targeting of intestinal parasites affecting sheep, cattle, goats and horses, Mr Lawlor said the opportunity to put Australian agriculture  ‘ahead of the curve’ was an exciting one. “ Globally, the losses from parasites would be in the tens of billions of dollars. “ I didn’t want to see the science to arrest this scourge developed overseas and then see Australian farmers having to buy it back.”  Even after the CSIRO discontinued its involvement in the project in 2004, Mr Lawlor refused to abandon the idea and continued pilot testing on his own property. According to Mr Lawlor, the next two decades involved 19 trials and three different safety studies including a plethora of testing and an encyclopaedic volume of reports. “It was something that had never been done before, so there was no rule book.” “It was like moving up through the levels of a video game,” Mr Lawlor said. “Each level was more and more difficult.” Two decades on, and universally acknowledged as one of the most significant recent breakthroughs in area of parasitology, Chris and his team’s work is about to have a major global economic and environmental impact, particularly in the area of agriculture where resistance to chemical drenches is now at alarming levels. "The fact is we’ve put Australia at the forefront of scientific advancement in livestock parasitology. “For the first time, we can now successfully treat multiple parasites in different grazing animals with a naturally occurring fungus – something that has never been done before.  “It has been a long and very difficult journey to not only develop and gain approval from various regulatory bodies around the world but keep the research, development and technology right here in Australia. BioWorma has been approved for sale in Australia and New Zealand and the USA where it will be released in early 2019, and Mr Lawlor said he hopes it will be available in Europe within the 12 to 18 months. For more information, visit https://www.bioworma.com ends. Embargoed: 12.30pm - November 21.   World-leading Science Museum Group curates digital transformation 2018-11-13T02:50:21Z world-leading-science-museum-group-curates-digital-transformation BRISBANE, 13 November 2018 – The UK’s world-leading group of science museums, The Science Museum Group (SMG) which attracts five million visitors per annum, has selected Australia’s largest enterprise Software as a Service company TechnologyOne (ASX:TNE) to modernise and transform its existing financial business system. TechnologyOne Chief Operating Officer, Stuart MacDonald said “The Science Museum Group stands among several new world-leading customers that have chosen TechnologyOne’s Software as a Service offering to transform their business. “The Science Museum Group’s new Software-as-a-Service (SaaS) solution from TechnologyOne has now gone live; empowering the group to streamline their financial operations to support their growth,” Mr MacDonald said. The Science Museum Group transacts an average of five million visitors each year. With around 1,000 employees and over 500 volunteers, the group required a robust and intuitive solution that would enable the finance team and other users, to access real-time information quickly and efficiently anywhere – on any device. Jane Ellis, Director of Corporate Services at Science Museum Group explained that: “As an organisation in the cultural sector we recognise the importance of actively responding to the challenges that lie ahead. With an increased requirement to generate income and make more efficient use of resources, we felt that our existing finance system no longer met our needs. We knew that multiple workarounds were being used in order to deliver financial outputs and all too often these were manual and time-consuming processes.  Furthermore, we wanted a user-friendly system, accessible from any device, with real-time reporting for our end users.” The new solution has gone live and provides the Science Museum Group with an intuitive system, that allows both finance and non-finance users to easily interrogate real-time data, quickly produce reports and efficiently make strategic decisions. “TechnologyOne demonstrated their ability to meet all of our requirements and provide a solution on time and to budget which delivers against our long-term goals of innovation and transformation. The new solution goes some way to enabling the Group to realise its digital first vision, as well as being adaptable and complying with current legislation,” said Ms Ellis. Anwen Robinson, UK Operating Officer at TechnologyOne, commented: “The public sector is an increasingly challenging environment to operate in so implementing the right SaaS technologies that are both flexible and enable the organisation to future-proof is vital. As the most significant group of science and innovation museums worldwide, it stands to reason that the Science Museum Group is embracing financial transformation to ensure it inspires interactive science for decades to come.” - Ends - About TechnologyOne TechnologyOne (ASX:TNE) is Australia's largest enterprise software company and one of Australia's top 200 ASX-listed companies, with offices across six countries. We create solutions that transform business and make life simple for our customers. We do this by providing powerful, deeply integrated enterprise software that is incredibly easy to use. Over 1,200 leading corporations, government departments and statutory authorities are powered by our software. We participate in only eight key markets: government, local government, financial services, education, health and community services, asset intensive, project intensive and corporate. For these markets we develop, market, sell, implement, support and run our preconfigured solutions, which reduce time, cost and risk for our customers. For over 30 years, we have been providing our customers enterprise software that evolves and adapts to new and emerging technologies, allowing them to focus on their business and not technology. Today, our software is available on the TechnologyOne Cloud and across smart mobile devices. For further information please visit: TechnologyOneCorp.com   About the Science Museum Group We are the world’s leading group of science museums, welcoming over five million visitors each year to five sites: The Science Museum in London; the National Railway Museum in York; the Museum of Science and Industry in Manchester; the National Science and Media Museum in Bradford; and Locomotion in Shildon. We share the stories of innovations and people that shaped our world and are transforming the future, constantly reinterpreting our astonishingly diverse collection spanning science, technology, engineering, mathematics and medicine. Standout objects include the record-breaking locomotive Flying Scotsman, Richard Arkwright’s textile machinery, Alan Turing’s Pilot ACE computer and the earliest surviving recording of British television. Our mission is to inspire futures - igniting curiosity among people of all ages and backgrounds. Each year, our museums attract more than 600,000 visits by education groups, while our touring exhibition programme brings our creativity and scholarship to audiences across the globe. More information can be found at:  www.group.sciencemuseum.org.uk   Kesem Health – Finalist, 2018 Australian Technologies Competition 2018-11-11T23:38:37Z kesem-health-finalist-2018-australian-technologies-competition-1 Kesem Health is honoured to be a finalist in the 2018 Australian Technologies Competition sponsored by The Department of Industry Innovation and Science, MTPConnect, METS Ignited, AustCyber, NERA and FIAL. Kesem Health is one of the top 9 incredible finalists that have been handpicked by the ATC Judges; earmarked as possessing some of Australia's greatest global potential. Kesem are the 'survivors' following 199 applications and 34 semi-finalists during 2018. The Competition serves to recruit, mentor and promote Australian's most promising technology start-ups and scaleups across a wide range of industries. Kesem Health developed and is commercialising the iUFlow™ solution to improve, simplify, and reduce the cost of the diagnosis and management of Lower Urinary Tract diseases including Benign Prostatic Hyperplasia (BPH), Overactive Bladder (OAB), and Nocturia.   SAS boosts the analytics behind life-saving drug development 2018-11-08T22:16:11Z sas-boosts-the-analytics-behind-life-saving-drug-development Cary, NC (Nov 07, 2018) To conduct clinical trials and develop new therapeutics, health organizations must manage and analyze staggering amounts of data. For decades, SAS® has been the gold standard for the life sciences industry. This week, SAS’ next-generation solutions for clinical trial data analysis and real world evidence debuted at PhUSE EU Connect in Frankfurt, Germany. The SAS Life Science Analytics Framework and SAS Real World Evidence deliver analytics, visualization, and modern AI and machine learning capabilities to organizations working with a growing variety of health-related data. New functionality improves their ability to evaluate new drug compounds, explore patient and efficacy data, and bring new therapies to market more quickly and safely than ever. SAS offered live demos of both solutions during this week’s PhUSE EU Connect conference. US audiences can experience the demos at PhUSE US Connect in Baltimore, Feb. 24-27, 2019. A singular analytics foundation for clinical research From small biotech entities just getting started in clinical development to large pharmaceutical enterprises with thousands of users, organizations have long relied on the SAS Life Science Analytics Framework. The cloud-based solution enables clinical researchers to manage and analyze trial information in a collaborative platform as well as deliver trial results to regulatory authorities. New functionality will allow them to do so even more efficiently: The customizable clinical repository hierarchy enables secure information access and collaboration between different organizational functions. A new SAS program development environment speeds up robust statistical result generation, reducing time to market of new therapies. The model-driven foundation for CDISC standards governance and enhanced study metadata management drive efficiency from study setup to submission Santen, a leading ophthalmology specialty company, uses the SAS Life Science Analytics Framework to speed development of new ocular therapies. The solution provides a singular, centralized and auditable clinical data repository for a multidisciplinary research team located in more than half a dozen countries in Asia, Europe and North America. “As a global organization, it is critical we have consistent, seamless access and version control across all the various groups at Santen, and the SAS Life Science Analytics Framework delivers just that,” said Nina Worden, Director of Statistical Programming at Santen. “The advances built into the new end-to-end clinical analytics framework will translate into less time wrangling with operational data management and more time developing innovative treatments that help preserve vision and health of people around the world.” Going beyond clinical trial data Regulators like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have underscored the importance of real world data – or observational data collected beyond controlled clinical trials – to assess the safety and efficacy of new drugs and medical devices. This data comes from electronic health records, claims and billing, disease registries, and even wearables and social media. Real world data holds tremendous potential to help the industry better design and conduct clinical trials, assess health care use across populations and identify at risk patients. SAS Real World Evidence gives organizations a means to tap this potential, aligning the most advanced analytic technologies to collect and derive intelligence from such data. The latest features and capabilities include: Data optimization for querying reduces the time to build a cohort and speeds time to insight. The ability to share cohorts, projects and data fosters greater collaboration between users who have SAS programming skills and those who prefer not to program. Users can use validated algorithms for analysis or incorporate their own macro libraries to increase access to data, analyses and insights across the organization. “SAS is ahead of the curve in addressing the ongoing convergence of health care and the life sciences,” said Ari Yacobi, Chief Data Scientist at Knowledgent, a health data analytics consulting firm. “Payers, providers, pharmaceutical sponsors and governments want easy access to leading machine learning algorithms informed by industry-standard clinical diagnosis and episode-of-care definitions. SAS Real World Evidence is the best tool we’ve seen on the market to address where the industry is headed.” Robust analytics transforming health and life sciences “SAS is the only vendor with this breadth of experience and offering comprehensive solutions for both clinical development and real-world, observational data analysis, inclusive of data management, traceability and regulatory needs,” said Mark Lambrecht, Director of the Global Health and Life Science Practice at SAS. “With these updated solutions, we’ve built upon our industry expertise to provide even more extensive capabilities to manage, analyze and visualize diverse types of patient data across the full drug development spectrum.” SAS will host a two-part webinar exploring how the latest advances in analytic technology, including artificial intelligence (AI) and the Internet of Medical Things, is transforming the health and life science industries. Register today: The Future of Advanced Analytics in Clinical Research (Nov. 8 at 10 a.m. ET) – Learn how data and analytics are shaping the different stages of clinical research, ultimately helping life sciences companies bring life-changing therapies to market faster while improving safety and reducing costs. Real-World Evidence and the Convergence of Life Sciences and Health Care (Nov. 15 at 10 a.m. ET) – Discover how AI and advanced analytics power pragmatic trials that yield better therapies, get life-changing therapies to patients faster, and use real world data to deliver better, more personalized treatment plans. About SAS SAS is the leader in analytics. Through innovative software and services, SAS empowers and inspires customers around the world to transform data into intelligence. SAS gives you THE POWER TO KNOW®. Clover adds spray drying capacity with investment in Melody Dairies, New Zealand 2018-11-04T23:04:44Z clover-adds-spray-drying-capacity-with-investment-in-melody-dairies-new-zealand-1   Melody Dairies Ltd Partnership will finance a dedicated Nutritional Spray Drying facility to be built in Waikato Innovation Park, Hamilton, New Zealand (NZ) Clover holds a 35% share with equivalent rights of access for spray drying its products This facility is the second dryer at the Food Innovation Waikato Park in NZ It provides additional capacity to meet growing demand for Clover’s products Clover has financed the purchase through a $11m debt facility     Clover Corporation Ltd (ASX:CLV) today announced it has acquired a 35% stake in a new company, Melody Dairies, based at the Waikato Innovation Park in Hamilton, New Zealand. The company is owned by four partners; New Zealand Food Innovation Waikato (NZFIW) 10%, Dairy Nutraceuticals Investment Limited (DNL) 20%, Landcorp Farming Limited (LFL) 35% and Nu-Mega Ingredients (NZ) Limited (NMI) 35% – a company wholly owned by Clover Corporation. The partnership in Melody Dairies is an extension of the relationship Clover has had with NZFIW since 2014, when Clover invested in the first spray dryer built at Waikato.    An industrial spray dryer is a multimillion dollar facility for converting large volumes of liquid (such as milk) into a dried form (milk powder) for ease of use, transport and storage.  The additional dryer, which will be owned by the partners in Melody Dairies, will augment the capacity of Clover to manufacture its range of specialty micro-encapsulated powders which service the infant formula, pharmaceutical, nutraceutical and functional food markets. This move reflects the increasing demand for Clover’s products, sales having grown by more than 20% annually over the past 4 years.   The additional dryer owned by Melody Dairies will be a specialist nutritional dryer at 1.2 metric ton drying capacity per hour, providing options for manufacturing Clover’s specialty products, and increasing capacity to supply the growing New Zealand infant formula market.  Clover maintains relationships and contracts providing access to third party spray drying facilities which will continue to provide manufacturing capacity for much of the Company’s product requirements. Clover Corporation has a range of patented micro-encapsulated products created through the spray drying process and containing omega 3 oils. These unique products are recognised in the infant formula sector as best in class for delivering high levels of DHA (a key component in omega 3 oils) with no sensory issues of taste or smell and twenty-four-month shelf life without the need for refrigeration.   These are attractive features for infant formula manufacturers who need to ensure the high quality of their products according to market requirements. Governments are increasingly legislating the requirement for DHA in infant formula to match the levels found naturally occurring in breast milk.  DHA is clinically recognised as a required nutrient for normal brain, eye and cardiovascular function, and is being used to fortify functional foods targeting sports, children and senior’s nutrition to support cognitive and physical performance, in addition to its use in infant formula.   Mr. Peter Davey, Clover Corporation’s CEO & Managing Director, noted that this investment will position Clover to meet the fast-growing demand for its products from both the infant formula and functional food markets.  “The acquisition of a significant share in Melody Dairies is part of the company’s strategy to vertically integrate into its supply chain. It will reduce the risk for both customers and the company of disruption to product supply which could result from problems of availability or quality at other facilities and allow for expansion of the supply chain to meet new opportunities” he said. Since its 2014 investment at Waikato, Clover has increased its production at the facility well beyond the original contracted volume, as it has at its alternative manufacturing facilities. The relationship with NZFIW has been excellent, which has made the partnership with NZFIW a logical and easy choice for further investment. Melody Dairies will be managed by the existing NZFIW facility team and board. Clover Corporation has invested in the business through debt funding, with the factory being built over the next two years (allowing for construction and qualification). For further information, please contact: Mr Rupert Harrington – Chairman Clover Corporation +61 3 8347 5000 Mr Peter Davey – MD & CEO Clover Corporation +61 3 8347 5000     About Clover Corporation Limited   Clover Corporation is an Australian company listed on the Australian Stock Exchange (ASX:CLV). Clover evolved from being a research and development, manufacturing and marketing company to one concentrating on forming strategic relationships focused on technology, new product development and commercialisation. Clover's superior microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods and beverages. Developed through extensive research and development, our proprietary technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. All of our products reach the highest standards of purity, stability and performance, allowing customers to maximise and deliver nutrition.   For more information about Clover visit www.clovercorp.com.au ADOLESCENT BACK PAIN MAY HERALD LIFETIME OF ILL HEALTH 2018-10-08T21:36:50Z adolescent-back-pain-may-herald-lifetime-of-ill-health According to new research[1] adolescent back pain may predict poor overall health, and risk of chronic disease throughout life. The New Zealand Chiropractors’ Association (NZCA) is concerned that chiropractic care is an underused option in the management of back pain and spinal health among New Zealand teenagers, and believe it could minimise the unnecessary use of pharmaceuticals[2] and help establish a better foundation for adult wellbeing.   Chiropractor and NZCA spokesperson Dr Cassandra Fairest explains: `This new study in the Journal of Public Health indicates that adolescents who experience back pain more frequently are also more likely to smoke cigarettes, drink alcohol, and report mental health conditions like anxiety and depression. But too few of them are seeking chiropractic care, which was recently cited in a major call to action by the Lancet as a drug free approach to the management of back pain’.   `The authors of this study point out that during adolescence, the prevalence of musculoskeletal pain in general, particularly back pain, rises steeply. Although often dismissed as trivial and fleeting, adolescent back pain is responsible for substantial health care usage, school absence, and interferes with day-to-day activities in some children.’   Researchers used data collected from approximately 6500 teenagers. The proportion of participants reporting smoking, drinking, and missing school rose incrementally with increasing frequency of pain. For example, 14-15 year olds that experienced pain more than once a week were 2-3 times more likely to have drunk alcohol or smoked tobacco in the past month than those who rarely or never had pain.   Similarly, students that experienced back pain more than once a week were around twice as likely to have missed school during the previous school term. The trend with anxiety and depression was less clear, although there was a marked difference between the children who reported no pain, and those who reported frequent pain.   Dr Fairest says: `The researchers found that back pain and unhealthy behaviours not only occur together, but also persist into adulthood. In addition, the developing brain is susceptible to the negative influences of toxic substances, and use in early adolescence may increase the risk of substance abuse and mental health problems in later life.’   The Lancet, one of the world’s most prestigious medical publications, has said in a series of articles that healthcare system changes are crucial to changing behaviour and improving the delivery of effective care for back pain. It recommends integrating and supporting health professionals from diverse disciplines to provide patients with consistent messages about mechanisms, causes, prognosis and natural history of low back pain, as well as the benefits of improved spinal health, physical activity and exercise. Chiropractic is ideally placed to play a pivotal role in this development.   Dr Fairest says: `We do have to ask ourselves why some New Zealanders are still being prescribed pain medication which may cause side effects when chiropractic care may be just as, or even more effective, and offer better long term outcomes? Chiropractors are uniquely placed to provide care that specifically focuses on the health of the spine and the relationship between the spine and the nervous system, both of which are clearly relevant to this population’s presentations. It seems that there’s a disconnect between patient choices and evidence-based guidelines for low back pain based upon what is actually happening within our healthcare system. It appears GP’s are encouraging people to rely on medication and are only considering chiropractic care after pharmaceutical treatments have failed instead of making a referral to a chiropractor a first-line treatment option, as per the research.’   New Zealand’s chiropractors are taking the lead to inform, and inspire people to prevent pain and disability by educating the public to have a greater understanding of the relationship between their spine and nervous system, improving their posture, addressing and preventing spinal problems, and engaging in physical activity.     ­Ends­ Further Information: Dr Cassandra Fairest, Chiropractor 021 242 3073 or cassandra.fairest@chiropractic.org.nz Peter Boyes 027 554 0500 or peter@boyespr.co.nz 1.     [1] S J Kamper, Z A Michaleff, P Campbell, K M Dunn, T P Yamato, R K Hodder, J Wiggers, C M Williams. Back pain, mental health and substance use are associated in adolescents. Journal of Public Health, 2018; DOI: 10.1093/pubmed/fdy129   [2] Low back pain: a call for action Lancet Volume 391, No. 10137, p2384–2388, 9 June 2018 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30488-4/fulltext     NEW AUSTRALIAN PARTNERSHIP FORMS TO BRING WORLD'S FIRST NON-INVASIVE MELANOMA TEST TO MARKET 2018-10-04T17:29:01Z new-australian-partnership-forms-to-bring-world-s-first-non-invasive-melanoma-test-to-market Melaseq will offer over two million Australians at high-risk of developing melanoma in their lifetime access to a simple blood test to detect melanoma signatures in their blood. Melaseq is also suited to tissue sample testing. With no specific solid tissue, blood or genetic detection tests available worldwide, doctors will welcome Melaseq for its accuracy and ability to improve clinical decision making and the monitoring of patients at risk of developing melanoma or those with re-emerging melanoma.  Once fully commercialised, Melaseq will for the first time, offer physicians a diagnostic tool to monitor for early signs of melanoma recurrence, potentially allowing life-saving treatment to start earlier. The partnership with Clinical Labs achieves an important milestone for Geneseq, a wholly owned Australian company. With the backing of Australia’s largest privately-held pathology company, Geneseq can accelerate additional testing and validation work at the scale required to bring Melaseq to the market.  Dr Ryan Van Laar PhD, CEO of Geneseq Biosciences said, “We are thrilled to be partnering with Clinical Labs, a company highly regarded as an early adopter of new technologies, such as precision medicine. This agreement gives us access to a world-class clinical and bio-specimen network, in addition to the reimbursement, regulatory, and commercial expertise necessary to make Melaseq a success”. Group CEO and Managing Director of Clinical Labs, Melinda McGrath said the new partnership is another demonstration of our strategy to innovate and grow through scientific leadership, market-leading technology and talented people. “We are delighted to be part of the early detection of melanoma. Australia has the largest incidence of skin cancer in the world and we want to this to change. Partnering with Geneseq Biosciences presents an exciting opportunity to find new ways to detect and prevent melanoma sooner,” she said. About the Research The partnership began after research was published in the peer-reviewed British Journal of Cancer in March 2018. This study revealed how Dr Van Laar and colleagues worked to discover a new signature of melanoma based on circulating microRNAs, found in patient and normal donor blood samples. In independent validation patient series, Melaseq exhibited up to 94% accuracy. A second clinical validation study has been accepted for publication in the Melanoma Research journal.  Reference #1: Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. British Journal of Cancer. 2018. Reference #2: Van Laar R, Lincoln M, Van Laar B. A Plasma MicroRNA Biomarker of Melanoma as a Personalised Assessment of Treatment Response. Melanoma Research. 2018 [In Press].   About Melanoma Two in three Australians will be diagnosed with skin cancer during their lifetime, of which melanoma is the rarest but most deadly form. Worldwide, the incidence of melanoma continues to increase, outpacing the rise of any other malignancy in the Caucasian population over the last 30 years [1, 2]. Despite being curable if diagnosed early, four Australians die each day from this cancer, resulting in more deaths than the road toll. If not diagnosed early and accurately, melanoma grows quickly spreads through the lymphatic system and blood stream to other organs such as the lungs, liver, brain or bone. There are currently no specific solid tissue, blood or genetic tests available to help doctors diagnose melanoma or monitor for recurrence. In 2018 there will be an estimated 14,320 melanoma diagnoses, 1,905 deaths and over 50,00 people living with the disease. Over 2 million Australians have one or more high-risk characteristics for developing melanoma in their lifetime.  About Australian Clinical Labs Australian Clinical Labs combine pathology leadership, ground-breaking technology and the best scientists in the field to bring better outcomes for doctors and patients alike.  Clinical Labs is the largest pathology provider to public hospitals in Australia and one of the top choices amongst private practices across the country. With over 90 NATA accredited laboratories and 900 collection sites nation-wide, the company performs around 8 million episodes a year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. Clinical Labs is a leader in molecular testing and new technologies and employs over 3,800 employees including more than 90 highly respected and experienced pathologists.  For more information about Clinical Labs please see: www.clinicallabs.com.au   About Geneseq Biosciences: Geneseq Biosciences is a privately-held Melbourne based biotechnology company, pioneering the development of new “liquid biopsy” tests to help doctors individualise cancer diagnostics & treatment options. Founded in 2016, their first test, Melaseq, is designed to accurately detect the genetic (microRNA) fingerprint of active melanoma in blood. In 2017, Geneseq Biosciences presented their work at the World Melanoma Congress and participated in the Royal Melbourne Hospitals ‘Melbourne Health Incubator (MHx)’ program. For more information about Geneseq please see: www.geneseq.com.au Flick Anticimex acquires eastern Sydney pest control business 2018-10-03T00:06:03Z flick-anticimex-acquires-eastern-sydney-pest-control-business Flick Anticimex has acquired Sentinel Pest Control, a local pest control business operating in Richmond. Sentinel Pest Control currently provides commercial, residential, and pre-construction pest control to customers across the greater Sydney region. This is Flick Anticimex’s third acquisition in Australia this year, preceded by the acquisitions of The Pest Guys in Perth, WA and South Coast Pest Control in South Coast, NSW. As of the end of September 2018, Flick Anticimex has acquired a total of seven businesses in the Australia and New Zealand market. Flick Anticimex looks forward to the continued expansion in these two markets. Commenting on the new acquisition, Guido Toepfer (President of the Anticimex Pacific Region): Sentinel is a high-quality provider of pest control and preconstruction services in the greater Sydney area. A family business with 40 years of experience the owners and employees share our view of the market, our values and customer focus. We will be stronger together, and that’s what it is all about. I am very much looking forward to our cooperation. Mental Health Needs a Holistic Approach Says Osteopath 2018-09-28T02:03:25Z mental-health-needs-a-holistic-approach-says-osteopath Long-term anxiety affects physiology, says James and the outcomes, if not addressed, can be very serious. Increased heart rate and blood pressure can expose the body to increased levels of cortisol which can lead to cardiovascular disease says James. According to Harvard Health anxiety is a reaction to stress that has both psychological and physical features. The feeling is thought to arise in the amygdala, a brain region that governs many intense emotional responses. Its biological source is for fight or flight response- to get us going! When attacked by a predator, the fight-or-flight response revs up the metabolism and prepares the body for vigorous activity, and most or all mammals share it. This is well and good if we are being chased by a Sabertooth tiger, but if you are are carrying stress unnecessarily it can cause havoc for your body holistically. Digestion, memory and chronic pain can also be a result amongst other long-term health implications. So what does it mean to have a holistic approach to health in combatting anxiety? How does preventative health assist? “Holistic means the parts of something are intimately interconnected and explicable only by reference to the whole,” says James. Therefore when we speak of Holistic health, it means we are addressing the physiological being as a whole- mind, and body.” “From an osteopathic perspective- connection and human movement are intrinsic parts of the whole, so addressing anxiety and spreading awareness is incredibly important as is reducing the stigma associated with mental health. Communication is key and being able to discuss how our body and mind are feeling openly.” According to Beyond Blue  anxiety conditions may develop because of one or more stressful life events. Common triggers include: work stress or job change change in living arrangements pregnancy and giving birth family and relationship problems major emotional shock following a stressful or traumatic event verbal, sexual, physical or emotional abuse or trauma death or loss of a loved one. If you or someone you know needs some help with anxiety or depression please see the following https://www.beyondblue.org.au/get-support/national-help-lines-and-websites. BOC South Pacific appoints Michelle Blume to Head of Human Resources 2018-09-26T04:23:36Z boc-south-pacific-appoints-michelle-blume-to-head-of-human-resources-1 Sydney, 26 September 2018: BOC, A Member of the Linde Group, a leading gases and engineering company, today announced the appointment of Michelle Blume to Head of Human Resources, Region South Pacific. A dedicated HR and business leader with a career at BOC spanning over two decades, Michelle has excelled in various HR, customer and finance roles including her most recent position as General Manager Remuneration & HR Systems. As Head of Human Resources, Region South Pacific, Michelle will lead HR for BOC across the region, including its subsidiaries Elgas and the South Pacific Welding Group. John Evans, BOC South Pacific Managing Director, said Michelle’s passion for coaching and leadership development, as well as her deep understanding of the employees across the South Pacific region, will deliver great value to the HR team and overall business. “We are delighted to welcome Michelle to the Regional Executive Board and look forward to working with her as we focus on building capability and driving collaboration across our workforce.” “Her broad range of skills in finance, leadership, change management and HR – and ability to understand people and their abilities has made her a trusted leader. This was recognised last year when she was appointed as a Trustee Director on the BOC Super Trustee Board.” Michelle Blume, Head of Human Resources, Region South Pacific said it is an honour to lead the wider HR team which covers the full range of HR services from diversity and talent management, right through to HR operations and superannuation. “My key focus is to work with the business to foster a diverse and inclusive workforce where all employees can reach their potential,” said Michelle. “By continuing to develop the skills in our people needed for our future workforce, engaging our employees and setting them up for success, we will continue to be an employer of choice.” Michelle Blume is a Trustee Director on the BOC Super Trustee Board. A certified member of the Australian Human Resources Institute, Michelle is also a Master Practitioner in Neuro Linguistic Programming and qualified practitioner in DISC, Myers Briggs (MBTI) and human synergistic tools (LSI, LI & OCI). IMC19 brings the future of science into focus 2018-09-25T22:43:44Z imc19-brings-the-future-of-science-into-focus-1 Critical discoveries and research that will help to transform health, science and industry are set to be the lasting legacy of the 19th International Microscopy Congress (IMC19), according to leaders of the scientific world. Held every four years, IMC19 saw more than 2,100 of the world’s top scientists and researchers from 48 countries come together at ICC Sydney to network, collaborate and discover the latest high-tech instrumentation and systems in microscopy and microanalysis. IMC19 also inspired the next generation of young scientists with its Schools Outreach Program, which welcomed 570 students from 19 schools. The program also featured a “Young Scientists Assembly” where 50 young scientists from around the world enjoyed the opportunity to discuss career planning with some of the most senior figures in the field. Professor Simon Ringer, Congress Chair, said the impact of IMC19 would be revealed over time from the global scientific community. “Innovations in microscopy enable us to extend our understanding of ourselves and the world around us. IMC19 brought together leaders in both the development and the application of microscopy in a huge range of disciplines,” he said. “These connections will ultimately lead to breakthroughs, as researchers take the insights from advanced microscopy to develop a treatment for cancer, a vaccine for a virus, or a new 3D printed metallurgical alloy that improves our atmosphere by being strong and light and thereby fuel and greenhouse gas efficient.” The week-long scientific program included presentations by four expert plenary speakers, two Nobel Laureates, 150 invited presenters as well as 26 pre-congress workshops and 463 oral talks, bridging the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. The pioneering IMC19 Outreach Learning Program welcomed high school students to experience the very latest light and electron microscope equipment and a chance to meet with researchers and specialists in microscopy. Mrs Diane Fairweather, Head of Science, Riverstone High School, said the program allowed students to access cutting-edge technology. “This was a great STEM initiative by IMC19 and an amazing experience for the students who came. We don’t have these microscopes at our school and without the IMC19 Outreach Program, most of our students wouldn’t be able to use this equipment,” said Fairweather. “Our students are engaged; they are learning directly from experts on things like using the lens to focus – it’s a real hands-on experience.” The Outreach Program offered students access to the latest equipment including, VR, four scanning electron microscopes, 20 life microscopes and 3D printing. Equipment and demonstrations were supported by Zeiss, Leica, AXT, Keepad Interactive, NewSpec, ATA, Coherent, UNSW Art and Design and Me3D. Citing recent examples of some of the life-changing advancements that have developed as a direct result of microscopy, Dr Alan Finkel, Australia’s Chief Scientist, inspired the audience at IMC19 and set the scene for a week of breakthroughs in his opening address. “An investment in this field (microscopy) is an investment in nanoparticles that target such things as a drug directly to malignant cells; 3D printed lattices that act like tiny factories for T-cells; vital in the new generation of cancer immunotherapies and more,” said Dr Finkel. “Without Microscopy, there is no modern science – end of story.” Professor Paul Munroe, Congress Co-Chair, said IMC19 had laid the foundations for great things. “We are excited to see where the collaborations from IMC19 take the industry, and what new technology and research will be showcased at the next congress in Korea in 2022,” he said. For more information on IMC19 visit: http://imc19.com. IMC19 brings the future of science into focus 2018-09-25T22:34:39Z imc19-brings-the-future-of-science-into-focus Critical discoveries and research that will help to transform health, science and industry are set to be the lasting legacy of the 19th International Microscopy Congress (IMC19), according to leaders of the scientific world. Held every four years, IMC19 saw more than 2,100 of the world’s top scientists and researchers from 48 countries come together at ICC Sydney to network, collaborate and discover the latest high-tech instrumentation and systems in microscopy and microanalysis. IMC19 also inspired the next generation of young scientists with its Schools Outreach Program, which welcomed 570 students from 19 schools. The program also featured a “Young Scientists Assembly” where 50 young scientists from around the world enjoyed the opportunity to discuss career planning with some of the most senior figures in the field. Professor Simon Ringer, Congress Chair, said the impact of IMC19 would be revealed over time from the global scientific community. “Innovations in microscopy enable us to extend our understanding of ourselves and the world around us. IMC19 brought together leaders in both the development and the application of microscopy in a huge range of disciplines” he said. “These connections will ultimately lead to breakthroughs, as researchers take the insights from advanced microscopy to develop a treatment for cancer, a vaccine for a virus, or a new 3D printed metallurgical alloy that improves our atmosphere by being strong and light and thereby fuel and greenhouse gas efficient.” The week-long scientific program included presentations by four expert plenary speakers, two Nobel Laureates, 150 invited presenters as well as 26 pre-congress workshops and 463 oral talks, bridging the primary streams of Frontier Issues; Instrumentation and Techniques; Physical and Life Sciences. The pioneering IMC19 Outreach Learning Program welcomed high school students to experience the very latest light and electron microscope equipment and a chance to meet with researchers and specialists in microscopy. Mrs Diane Fairweather, Head of Science, Riverstone Highschool, said the program allowed students to access cutting-edge technology. “This was a great STEM initiative by IMC19 and an amazing experience for the students who came. We don’t have these microscopes at our school and without the IMC19 Outreach Program, most of our students wouldn’t be able to use this equipment,” said Fairweather. “Our students are engaged; they are learning directly from experts on things like using the lens to focus – it’s a real hands-on experience.” The Outreach Program offered students access to the latest equipment including, VR, four scanning electron microscopes, 20 life microscopes and 3D printing. Equipment and demonstrations were supported by Zeiss, Leica, AXT, Keepad Interactive, NewSpec, ATA, Coherent, UNSW Art and Design and Me3D. Citing recent examples of some of the life-changing advancements that have developed as a direct result of microscopy, Dr Alan Finkel, Australia’s Chief Scientist, inspired the audience at IMC19 and set the scene for a week of breakthroughs in his opening address. “An investment in this field (microscopy) is an investment in nanoparticles that target such things as a drug directly to malignant cells; 3D printed lattices that act like tiny factories for T-cells; vital in the new generation of cancer immunotherapies and more,” said Dr Finkel. “Without Microscopy, there is no modern science – end of story.” Professor Paul Munroe, Congress Co-Chair, said IMC19 had laid the foundations for great things. “We are excited to see where the collaborations from IMC19 take the industry, and what new technology and research will be showcased at the next congress in Korea in 2022,” he said. For more information on IMC19 visit: http://imc19.com. Images: IMC19 Outreach Learning Program: Notes to editors: Interviews with Professor Simon Ringer, Congress Chair, IMC19 Interviews with Professor Paul Munroe, Congress Co-Chair, IMC 19 Media enquires contact Zadro Sinead Andrews | Account Coordinator | Zadro 02 9212 7867 | sinead@zadroagency.com.au Elizabeth Williams | Group Account Director | Zadro 02 9212 7867 | elizabeth@zadroagency.com.au NOTE: About the 19th International Microscopy Congress, 9 – 14 September 2018 Held once every four years, the International Microscopy Congress (IMC) is the preeminent meeting for researchers, practitioners, decision makers, national microscopy societies, industry partners and stakeholders involved in microscopy sciences from all over the world. Now in its 19th year, IMC19 ‘Microscopy: Bridging the Sciences’ is the only platform to bring together international, national and local professionals to discover new opportunities, uncover findings, learn techniques, collaborate with peers, and network with global leaders in the field of microscopy. About the Australian Microscopy & Microanalysis Society (AMMS) The Australian Microscopy & Microanalysis Society (AMMS) is Australia’s industry association for the promotion, co-operation and development of microscopy, microanalysis, and related techniques across a broad range of scientific disciplines. About the International Federation of Societies for Microscopy (IFSM) The International Federation of Societies for Microscopy (IFSM) comprises microscopy societies from all around the world to contribute to the advancement of microscopy in all its aspects. Millions of Lines of Code Offered on Open Platform Model for Healthcare Industry 2018-09-21T02:44:51Z millions-of-lines-of-code-offered-on-open-platform-model-for-healthcare-industry There are many secrets in the software development industry. Even more so when it comes to servicing the growing online needs of the healthcare industry. When it comes to complexity, the healthcare industry has systemic and functional needs that require the most rigorous intelligent designs. No wonder large organisations have their own IT departments dedicated to the analytics of building functional and practical solutions. Is it surprising that software developers guard their intellectual property behind walls of privacy? The demands are so vast that, even with their own IT departments the healthcare industry adopts existing applications. There are many software solutions out there and the freeware model is not new. There are even companies that offer blocks of code. But the functionality of this freeware is deliberately limited and building a system out of blocks is like trying to live in a house made out of Lego. The requirements, practices and compliance requirements of the healthcare industry make off-the-shelf software an unviable prospect. Add to this the fact that the larger an organisation is, the more demanding and complex their requirements become. There is a healthy supply of software development companies servicing medical practices that excel in meeting security, financial management, database, admin, privacy and compliance needs, who are also fully certified to deliver these solutions. Here’s the problem: you can get a pre-fabricated house design and then discover that when you put it on your block of land all of the main windows face west. The danger is software installed and then it becomes apparent with use that it doesn’t actually fit operational needs. Many companies have difficulty adopting new systems because of this inherent problem. No two businesses are the same. Every business has an internal structure that creates policies and procedures unique to them. This feature distends as a company grows, particularly in the area of medicine. There are certainly software packages that allow specialist medical practices to adapt their standard templates and branding. Like choosing a modular home that is customisable – you can change the package, choose from a selection of designs, customise it to suit your needs and fit your location. However, you are still restricted to the architectural design of the builders and no matter how customisable the forms, sometimes it just doesn’t solve specific functional needs of specialist practices. The intellectual property remains with the software builders and the only changes you can make are the ones they allow. But imagine if you were given superior designs and materials and then told you were allowed to bring in your own architect. This is what iTWorkS open platform allows – unrestricted access to some of the most complex medical software coding available. The advantages are enormous, particularly for large-scale specialist practices. Rather than trying to fit your system into someone else’s space, your IT specialists – who know best what your business needs – have unfettered access to iTWorkS coding and can modify it to fit your business family needs. There are no restrictions and no secrets. This is how iTWorkS open platform licensing model works. Claydata is currently rolling out the iTWorkS integrated practice management system with Australia's leading cardiac health provider. The benefits are outstanding: this leading global health provider will extrapolate an annual saving of $1.8 million, simply by automating 25 minutes of daily manual procedures across 16 admin points within their practices. Taking risks with innovation does pay off. Claydata, is releasing iTWorkS to the healthcare industry on the 26th of September by an Expression of Interest for the acquisition of its licence and is inviting leading healthcare institutions and their IT partners. Expressions of interest are being sought from healthcare software decision makers, senior representatives and their consultants. About registration your interest, and getting your information pack. Register Here Related Articles: Mirage News | Open Platform Software Set to Disrupt Healthcare Industry AAP Medianet | Open Platform Software Set to Disrupt Healthcare Industry Linkedin | Cutting-edge Tech bucks the trend and goes Open IssueWire Claydata Releases New Expression of Interest Linkedin | What Claydata has learned from Harvard Business School? LinkedIn | Australia's largest private cardiology group GenesisCare lead industry adoption of 'Open Platform' by Claydata | END | www.claydata.comCopyright © *|2018|* *|claydata|*, All rights reserved.